US BROKER MOVES: AEP upgraded at BTIG; AAPL downgraded at Loop Capital

• American Electric Power (AEP) Upgraded from Neutral to Buy at BTIG; PT USD 147
• Akamai Technologies (AKAM) Upgraded from Outperform to Strong Buy at Raymond James; PT USD 170
• Arhaus (ARHS) Upgraded from Neutral to Overweight at Piper Sandler; PT USD 13
• BlackRock (BLK) Upgraded from Hold to Buy at TD Cowen; PT USD 1,405
• Healthcare Realty Trust (HR) Upgraded from Hold to Buy at Deutsche Bank; PT USD 23
• Liberty Global (LBTYA) Upgraded from Neutral to Buy at New Street Research; PT USD 14
• TKO Group (TKO) Upgraded from Neutral to Buy at Arete; PT USD 208
• Trex (TREX) Upgraded from Hold to Buy at Stifel; PT USD 55
• Venture Global (VG) Upgraded from Equal Weight to Overweight at Wells Fargo; PT USD 21

• Apple (AAPL) Downgraded from Buy to Hold at Loop Capital; PT USD 330
• Elanco Animal Health (ELAN) Downgraded from Buy to Hold at Jefferies
• Essential Properties Realty Trust (EPRT) Downgraded from Buy to Hold at Deutsche Bank; PT USD 28
• EyePoint Pharmaceuticals (EYPT) Downgraded from Neutral to Underweight at JPMorgan
• EyePoint Pharmaceuticals (EYPT) Downgraded from Outperform to Neutral at Mizuho; PT USD 0.50
• NuScale Power (SMR) Downgraded from Equalweight to Underweight at Barclays; PT USD 5
• Zoetis (ZTS) Downgraded from Buy to Hold at Jefferies

• ADARx Pharmaceuticals (ADRX) Initiated at Buy at TD Cowen
• ADARx Pharmaceuticals (ADRX) Initiated at Buy at UBS; PT USD 35
• ADARx Pharmaceuticals (ADRX) Initiated at Overweight at Morgan Stanley; PT USD 32
• ADARx Pharmaceuticals (ADRX) Initiated at Overweight at JPMorgan; PT USD 38
• Artivion (AORT) Initiated at Buy at Jefferies; PT USD 31
• Baxter International (BAX) Initiated at Peer Perform at Wolfe Research
• Bicara Therapeutics (BCAX) Initiated at Overweight at Morgan Stanley; PT USD 41
• Becton Dickinson (BDX) Initiated at Outperform at Wolfe Research
• Climb Bio (CLYM) Initiated at Buy at Deutsche Bank; PT USD 28
• Ensysce Biosciences (ENSC) Initiated at Overweight at Cantor Fitzgerald; PT USD 2
• GE HealthCare (GEHC) Initiated at Peer Perform at Wolfe Research
• Genmab (GMAB) Initiated at Equalweight at Morgan Stanley; PT USD 42
• Hubbell (HUBB) Initiated at Neutral at JPMorgan; PT USD 485
• Immix Biopharma (IMMX) Initiated at Overweight at Morgan Stanley; PT USD 20
• Kestra Medical Technologies (KMTS) Initiated at Outperform at Evercore ISI; PT USD 34
• Kazia Therapeutics (KZIA) Initiated at Outperform at Leerink; PT USD 30
• Midera Food Processing (MFP) Initiated at Outperform at William Blair
• Modine Manufacturing (MOD) Initiated at Overweight at Cantor Fitzgerald
• MPLX (MPLX) Initiated at Neutral at JPMorgan; PT USD 62
• nVent Electric (NVT) Initiated at Overweight at JPMorgan; PT USD 167
• Orion180 Insurance Group (OIG) Initiated at Buy at Texas Capital Securities; PT USD 2
• Restaurant Brands International (QSR) Initiated at Outperform at Mizuho; PT USD 85
• Sunoco (SUN) Initiated at Overweight at JPMorgan; PT USD 87
• Thomson Reuters (TRI) Initiated at Buy at Jefferies; PT USD 130
• Tvardi Therapeutics (TVRD) Initiated at Buy at Chardan; PT USD 8
• Western Midstream (WES) Initiated at Neutral at JPMorgan; PT USD 50

Daily broker roundups of this kind are a standing feature of the US pre-market, and the established pattern is that the bulk of the list passes without lasting effect while one or two single-name calls on index heavyweights carry the tape. A downgrade on a mega-cap such as AAPL from Buy to Hold, particularly where the price target remains above the prevailing level, tends to be read as a valuation or positioning call rather than a change in the fundamental thesis, and historical precedent is that such notes move the stock at the open but rarely reset the consensus on their own. The cluster of initiations on a single small-cap biotech across multiple bulge-bracket and specialist banks is the signature of post-IPO syndicate coverage coming off restriction, a sequence that typically produces a batch of Buy and Overweight ratings on the same day rather than independent conviction. Paired downgrades within a sector, as with the animal health names here, are worth distinguishing from idiosyncratic calls since they more often reflect an analyst stepping back from a group view. The follow-on worth noting is whether any of the calls draw same-day responses from peer houses, which is where single-analyst moves have historically turned into sector-level repricing.